Lin, Yufei http://orcid.org/0000-0001-7257-3068
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Farrer, Lindsay A.
Xu, Hongqin
Henderson, David C.
Zhang, Huiping
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01AA025080, R21AA023068)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
Article History
Received: 24 July 2019
Revised: 22 January 2020
Accepted: 27 January 2020
First Online: 7 February 2020
Compliance with ethical standards
:
: This work was supported by grants (R21AA023068 and R01AA025080) from the National Institute on Alcohol Abuse and Alcoholism. HRK is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE), which during the past three years was supported by AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. HRK is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. All other authors declare that they have no conflict of interest. The authors alone are responsible for the content and writing of this paper.
: Ethics statements: The study was exempted from a specific ethical approval by Boston University School of Medicine in accordance with local/national guidelines. This study only involved DNA methylation data analysis, and the de-identified DNA samples were from our collaborator Dr Joel Gelernter at Yale University School of Medicine. Patient samples and demographic information were collected as part of previous studies (Krystal et al. [CitationRef removed]; Gelernter et al. [CitationRef removed]).